| Popis: |
Objective: The goal of this study was to develop and characterize an ion-activatedin situgel-forming Brimonidinetartarate (BT), solution eye drops containing sterculiafoetida gum as a mucoadhesive polymer. Method: sol-gel formulation was prepared by using gellan gum as an ion-activated gel-forming polymer, sterculiafoetida gum as mucoadhesive agent and hydroxy propyl methyl cellulose (HPMC E50LV) as release retardant polymer. Phenyl ethyl alcohol as preservatives in borate buffer. The 23 factorial design was employed to optimize the formulation considering the concentration of gelrite, sterculiafoetida gum and hydroxy propyl methyl cellulose as independent variables, gelation time, gel strength, mucoadhesive force (N). Viscosity (cP) and In-vitro percentage drug release were chosen as dependent variables. The formulation was characteristics for pH, clarity, isotonicity, sterility, rheological behavior, andin-vitrodrug release, ocular irritation, and ocular visualization. Result: Based on desirability index of responses, the formulation containing a concentration of gelrite (0.24%), sterculiafoetida gum (0.13%) and hydroxy propyl methyl cellulose (HPMC E50 (0.4%) were found to be the optimized formulation concentration developed by 23 factorial design. The solution eye drops resulted in an in-situphase change to gel-state when mixed with simulated tear fluid (STF). Drug release from the gel followed non-fickian mechanism with 94% of drug released in 10 h, thus increased the residence time of the drug. Conclusion: An in-situ gelling system is a valuable alternative to the conventional system with added benefits of sustained drug release which may ultimately result into improved patient compliance. KEYWORDS: Sterculia Foetida gum, Hen's Egg Test – Chorioallantoic Membrane [HET-CAM] Test Brimonidine Tartarate. |
